{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:15:48Z","timestamp":1787163348086,"version":"build-2736575974"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:00:00Z","timestamp":1758499200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>IMPORTANCE:<\/jats:title>\n                    <jats:p>Polymyxin B hemoperfusion (PMX-HP) is a potential therapeutic option for sepsis; however, its clinical effects remain unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>We explored the association between PMX-HP and clinical outcomes in patients in ICUs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DESIGN, SETTING, AND PARTICIPANTS:<\/jats:title>\n                    <jats:p>This is a multicenter prospective cohort study conducted in 20 ICUs in Japan between 2020 and 2022. Patients with septic shock requiring high-dose norepinephrine (\u2265 0.2 \u00b5g\/kg\/min) were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MAIN OUTCOMES AND MEASURES:<\/jats:title>\n                    <jats:p>We compared patient characteristics and outcomes between those who received PMX-HP (PMX group) and those who did not (non-PMX group). A primary outcome was 28-day mortality, with secondary outcomes including changes in mean arterial pressure (MAP) and vasoactive-inotropic score over time in the initial 48 hours, 28-day vasopressor-free days, and 90-day mortality rate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>\n                      Among 309 patients, 175 (56.6%) were males, with a median age of 72 years and an Acute Physiology and Chronic Health Evaluation II (APACHE II) score of 26. Overall, 82 patients underwent PMX-HP. The PMX and non-PMX groups had similar median ages (71 vs. 73 yr) and APACHE II scores (26 vs. 27). The median PMX-HP duration was 1016 minutes. The 28-day mortality was similar between the groups (PMX group: 17.1%, non-PMX group: 18.9%,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = 0.71), with an adjusted hazard ratio of 0.88 (95% CI, 0.46\u20131.68). MAP was maintained at a higher level with low-dose vasopressor from 8 to 32 hours following admission in the PMX group. The PMX group had fewer 28-day ICU-free days (16 vs. 18,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = 0.026). The 90-day mortality rate was similar between the groups (PMX group, 23.5%; non-PMX group, 27.1%;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = 0.62).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS AND RELEVANCE:<\/jats:title>\n                    <jats:p>PMX-HP was not associated with the 28-day mortality improvement but was associated with higher MAP and lower vasopressor use for 8\u201332 hours of admission. Our findings suggested that PMX-HP requires careful adaptation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/cce.0000000000001320","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T14:00:11Z","timestamp":1758549611000},"page":"e1320","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Polymyxin B Hemoperfusion for Patients With Septic Shock Requiring High-Dose Norepinephrine: A Multicenter Prospective Cohort Study"],"prefix":"10.1097","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4471-4788","authenticated-orcid":false,"given":"Yu","family":"Kawazoe","sequence":"first","affiliation":[{"name":"Department of Emergency and Critical Care Medicine, Tohoku University Hospital, Sendai, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyohei","family":"Miyamoto","sequence":"additional","affiliation":[{"name":"Department of Emergency and Critical Care Medicine, Wakayama Medical University, Wakayama, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Miyagawa","sequence":"additional","affiliation":[{"name":"Department of Emergency and Critical Care Medicine, Sendai Medical Center, Sendai, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Ohta","sequence":"additional","affiliation":[{"name":"Department of Emergency and Critical Care Medicine, National Hospital Organization Kyoto Medical Center, Kyoto, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Yamamura","sequence":"additional","affiliation":[{"name":"Department of Emergency and Critical Care Medicine, Japan Community Health Care Organization, Osaka Minato Central Hospital, Osaka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine and Critical Care Medicine, Saiseikai Utsunomiya Hospital, Utsunomiya, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukitoshi","family":"Toyoda","sequence":"additional","affiliation":[{"name":"Department of Emergency and Critical Care Medicine, Hiratsuka City Hospital, Hiratsuka, Kanagawa, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michihito","family":"Kyo","sequence":"additional","affiliation":[{"name":"Department of Emergency and Critical Care Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Emergency and Critical Care Medicine, Tohoku University Hospital, Sendai, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Kinjo","sequence":"additional","affiliation":[{"name":"Division of Critical Care Medicine, Nara Prefecture General Medical Center, Nara, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Division of Acute and Critical Care Medicine, Department of Anesthesiology and Critical Care Medicine, Hokkaido University Faculty of Medicine, Sapporo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Maruyama","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine and Critical Care, Fukuoka University Hospital, Fukuoka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Fukushima","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Matsuura","sequence":"additional","affiliation":[{"name":"Department of Emergency and Critical Care Medicine, Osaka Prefectural Nakakawachi Emergency and Critical Care Center, Higashi-Osaka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Murata","sequence":"additional","affiliation":[{"name":"Department of Emergency and Critical Care Medicine, Ehime University Graduate School of Medicine, Toon, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoya","family":"Okazaki","sequence":"additional","affiliation":[{"name":"Department of Emergency Medical Center, Kagawa University Hospital, Kida, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Sakurai","sequence":"additional","affiliation":[{"name":"Department of Emergency and Critical Care Medicine, National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Emergency and Critical Care Medicine, Fukushima Medical University, Fukushima, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasuku","family":"Hanajima","sequence":"additional","affiliation":[{"name":"Department of Trauma and Reconstruction Center, Shin-yurigaoka General Hospital, Kawasaki, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaku","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Critical Care and Disaster Medicine, Iwate Medical University, Morioka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Morimoto","sequence":"additional","affiliation":[{"name":"Department of Data Science, Hyogo Medical University, Nishinomiya, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,9,22]]},"reference":[{"key":"R1-20250922","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1001\/jama.2016.0289","article-title":"Developing a new definition and assessing new clinical criteria for septic shock: For the third international consensus definitions for sepsis and septic shock (Sepsis-3).","volume":"315","author":"Shankar-Hari","year":"2016","journal-title":"JAMA"},{"key":"R2-20250922","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1007\/s00134-020-06151-x","article-title":"Incidence and mortality of hospital- and ICU-treated sepsis: Results from an updated and expanded systematic review and meta-analysis.","volume":"46","author":"Fleischmann-Struzek","year":"2020","journal-title":"Intensive Care Med"},{"key":"R3-20250922","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1001\/jama.2017.13836","article-title":"Incidence and trends of sepsis in US hospitals using clinical vs claims data, 2009\u20132014.","volume":"318","author":"Rhee","year":"2017","journal-title":"JAMA"},{"key":"R4-20250922","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/CCM.0000000000006135","article-title":"Surviving Sepsis Campaign Research Priorities 2023.","volume":"52","author":"De Backer","year":"2024","journal-title":"Crit Care Med"},{"key":"R5-20250922","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1056\/NEJMoa2202707","article-title":"Restriction of intravenous fluid in ICU patients with septic shock.","volume":"386","author":"Meyhoff","year":"2022","journal-title":"N Engl J Med"},{"key":"R6-20250922","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1056\/NEJMoa1705835","article-title":"Adjunctive glucocorticoid therapy in patients with septic shock.","volume":"378","author":"Venkatesh","year":"2018","journal-title":"N Engl J Med"},{"key":"R7-20250922","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1056\/NEJMoa1704154","article-title":"Angiotensin II for the treatment of vasodilatory shock.","volume":"377","author":"Khanna","year":"2017","journal-title":"N Engl J Med"},{"key":"R8-20250922","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1744-9987.1998.tb00066.x","article-title":"Extracorporeal endotoxin removal by polymyxin B immobilized fiber cartridge: Designing and antiendotoxin efficacy in the clinical application.","volume":"2","author":"Shoji","year":"1998","journal-title":"Ther Apher"},{"key":"R9-20250922","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.3390\/ijms22042228","article-title":"Therapeutic rationale for endotoxin removal with polymyxin B immobilized fiber column (PMX) for septic shock.","volume":"22","author":"Shoji","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R10-20250922","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1001\/jama.2018.14618","article-title":"Effect of targeted polymyxin B hemoperfusion on 28-day mortality in patients with septic shock and elevated endotoxin level: The Euphrates randomized clinical trial.","volume":"320","author":"Dellinger","year":"2018","journal-title":"JAMA"},{"key":"R11-20250922","doi-asserted-by":"crossref","first-page":"7295","DOI":"10.1038\/s41598-023-34084-0","article-title":"Modifications of peripheral perfusion in patients with vasopressor-dependent septic shock treated with polymyxin B-direct hemoperfusion.","volume":"13","author":"Sekino","year":"2023","journal-title":"Sci Rep"},{"key":"R12-20250922","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1001\/jama.2009.856","article-title":"Early use of polymyxin B hemoperfusion in abdominal septic shock: The EUPHAS randomized controlled trial.","volume":"301","author":"Cruz","year":"2009","journal-title":"JAMA"},{"key":"R13-20250922","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s00134-015-3751-z","article-title":"Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: A multicenter randomized control trial.","volume":"41","author":"Payen","year":"2015","journal-title":"Intensive Care Med"},{"key":"R14-20250922","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1159\/000513213","article-title":"Effects of polymyxin B hemoperfusion on septic shock patients requiring noradrenaline: Analysis of a nationwide administrative database in Japan.","volume":"50","author":"Fujimori","year":"2021","journal-title":"Blood Purif"},{"key":"R15-20250922","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s13054-017-1712-3","article-title":"Potential survival benefit of polymyxin B hemoperfusion in patients with septic shock: A propensity-matched cohort study.","volume":"21","author":"Nakamura","year":"2017","journal-title":"Crit Care"},{"key":"R16-20250922","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/1744-9987.13655","article-title":"Effects of polymyxin B hemoperfusion in patients with sepsis requiring continuous hemodiafiltration: Analysis of a nationwide administrative database in Japan.","volume":"25","author":"Fujimori","year":"2021","journal-title":"Ther Apher Dial"},{"key":"R17-20250922","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s13054-023-04533-3","article-title":"Targeted therapy using polymyxin B hemadsorption in patients with sepsis: A post-hoc analysis of the JSEPTIC-DIC study and the Euphrates trial.","volume":"27","author":"Osawa","year":"2023","journal-title":"Crit Care"},{"key":"R18-20250922","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s40560-017-0214-3","article-title":"Prolonged direct hemoperfusion using a polymyxin B immobilized fiber cartridge provides sustained circulatory stabilization in patients with septic shock: A retrospective observational before\u2013after study.","volume":"5","author":"Miyamoto","year":"2017","journal-title":"J Intensive Care"},{"key":"R19-20250922","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1159\/000491744","article-title":"Mortality effects of prolonged hemoperfusion therapy using a polymyxin B-immobilized fiber column for patients with septic shock: A sub-analysis of the DESIRE trial.","volume":"46","author":"Kawazoe","year":"2018","journal-title":"Blood Purif"},{"key":"R20-20250922","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1159\/000515685","article-title":"Impact of extended duration of polymyxin B-immobilized fiber column direct hemoperfusion on hemodynamics, vasoactive substance requirement, and pulmonary oxygenation in patients with sepsis: An observational study.","volume":"51","author":"Mitaka","year":"2022","journal-title":"Blood Purif"},{"key":"R21-20250922","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1111\/aas.14519","article-title":"Noradrenaline dose cutoffs to characterise the severity of cardiovascular failure: Data-based development and external validation.","volume":"68","author":"P\u00f6lkki","year":"2024","journal-title":"Acta Anaesthesiol Scand"},{"key":"R23-20250922","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.bja.2018.12.019","article-title":"Vasoactive-inotropic score and the prediction of morbidity and mortality after cardiac surgery.","volume":"122","author":"Koponen","year":"2019","journal-title":"Br J Anaesth"},{"key":"R24-20250922","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s00134-021-06506-y","article-title":"Surviving sepsis campaign: International guidelines for management of sepsis and septic shock 2021.","volume":"47","author":"Evans","year":"2021","journal-title":"Intensive Care Med"},{"key":"R25-20250922","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s40560-021-00555-7","article-title":"The Japanese clinical practice guidelines for management of sepsis and septic shock 2020 (J-SSCG 2020).","volume":"9","author":"Egi","year":"2021","journal-title":"J Intensive Care"},{"key":"R26-20250922","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1097\/CCM.0000000000001142","article-title":"The impact of timing of antibiotics on outcomes in severe sepsis and septic shock: A systematic review and meta-analysis.","volume":"43","author":"Sterling","year":"2015","journal-title":"Crit Care Med"},{"key":"R27-20250922","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1056\/NEJMoa1703058","article-title":"Time to treatment and mortality during mandated emergency care for sepsis.","volume":"376","author":"Seymour","year":"2017","journal-title":"N Engl J Med"},{"key":"R28-20250922","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/1744-9987.12339","article-title":"Clinical effects of a longer duration of polymyxin B-immobilized fiber column direct hemoperfusion therapy for severe sepsis and septic shock.","volume":"19","author":"Yamashita","year":"2015","journal-title":"Ther Apher Dial"},{"key":"R29-20250922","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.jcrc.2014.03.031","article-title":"Polymyxin B-immobilized fiber column hemoperfusion removes endotoxin throughout a 24-hour treatment period.","volume":"29","author":"Mitaka","year":"2014","journal-title":"J Crit Care"},{"key":"R30-20250922","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jcrc.2020.02.014","article-title":"Relationship between norepinephrine dose, tachycardia and outcome in septic shock: A multicentre evaluation.","volume":"57","author":"Domizi","year":"2020","journal-title":"J Crit Care"},{"key":"R31-20250922","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jss.2021.03.042","article-title":"Hitting the vasopressor ceiling: Finding norepinephrine associated mortality in the critically Ill.","volume":"265","author":"Singer","year":"2021","journal-title":"J Surg Res"},{"key":"R32-20250922","doi-asserted-by":"crossref","first-page":"e446","DOI":"10.1002\/ams2.446","article-title":"Impact of timing of polymyxin B-immobilized fiber column direct hemoperfusion on outcome in patients with septic shock: A single-center observational study.","volume":"7","author":"Tanaka","year":"2019","journal-title":"Acute Med Surg"},{"key":"R33-20250922","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1159\/000501632","article-title":"Evaluation of proteins and cells that adsorb to dialysis membranes used in continuous hemodiafiltration: Comparison of AN69ST, polymethylmethacrylate, and polysulfone membranes.","volume":"48","author":"Michikoshi","year":"2019","journal-title":"Blood Purif"},{"key":"R34-20250922","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000444474","article-title":"Potential survival benefit of polymyxin B hemoperfusion in septic shock patients on continuous renal replacement therapy: A propensity-matched analysis.","volume":"42","author":"Iwagami","year":"2016","journal-title":"Blood Purif"},{"key":"R35-20250922","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1007\/s00134-018-5463-7","article-title":"Polymyxin B hemoperfusion in endotoxemic septic shock patients without extreme endotoxemia: A post hoc analysis of the Euphrates trial.","volume":"44","author":"Klein","year":"2018","journal-title":"Intensive Care Med"},{"key":"R36-20250922","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s40560-019-0386-0","article-title":"The wind changed direction and the big river still flows: From Euphrates to Tigris.","volume":"7","author":"Iba","year":"2019","journal-title":"J Intensive Care"},{"key":"R37-20250922","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1186\/s13054-021-03762-8","article-title":"Trends in the incidence and outcome of sepsis using data from a Japanese nationwide medical claims database\u2014the Japan Sepsis Alliance (JaSA) study group.","volume":"25","author":"Imaeda","year":"2021","journal-title":"Crit Care"}],"container-title":["Critical Care Explorations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCE.0000000000001320","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T14:00:16Z","timestamp":1758549616000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CCE.0000000000001320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,22]]},"references-count":36,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/cce.0000000000001320","relation":{},"ISSN":["2639-8028"],"issn-type":[{"value":"2639-8028","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,22]]}}}